BCLI:NSD-Brainstorm Cell Therapeutics Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 4.06

Change

+0.09 (+2.27)%

Market Cap

USD 0.14B

Volume

0.72M

Average Target Price

USD 12.00 (+195.57%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and in Phase II for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other central nervous system disorders. The company has a partnership with Catalent for the manufacture of NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-02-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

+6.43 (+4.33%)

USD58.72B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

-0.43 (-0.20%)

USD55.37B 20.70 14.64
REGN Regeneron Pharmaceuticals, Inc

-2.62 (-0.58%)

USD48.55B 14.85 12.06
ALXN Alexion Pharmaceuticals, Inc

-0.90 (-0.59%)

USD33.78B 56.49 34.28
BGNE BeiGene, Ltd

-9.73 (-2.95%)

USD29.41B N/A N/A
RPRX Royalty Pharma plc

-0.45 (-0.96%)

USD28.55B 22.60 14.73
BNTX BioNTech SE

-3.30 (-2.94%)

USD27.49B -99,999.99 N/A
SGEN Seagen Inc

+1.02 (+0.68%)

USD27.19B 44.54 41.48
GMAB Genmab A/S

+0.19 (+0.56%)

USD23.40B 26.59 3.51
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing BCLI

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -10.28% 18% F 9% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.28% 17% F 9% F
Trailing 12 Months  
Capital Gain -41.83% 9% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -41.83% 9% F 4% F
Trailing 5 Years  
Capital Gain 76.52% 64% D 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 76.52% 64% D 56% F
Average Annual (5 Year Horizon)  
Capital Gain 49.05% 78% C+ 89% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 49.05% 78% C+ 89% B+
Risk Return Profile  
Volatility (Standard Deviation) 76.08% 35% F 16% F
Risk Adjusted Return 64.46% 88% B+ 81% B-
Market Capitalization 0.14B 23% F 26% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 6.95 43% F 29% F
Price / Cash Flow Ratio -4.03 27% F 61% D-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -273.75% 9% F 3% F
Return on Invested Capital -272.66% 6% F 3% F
Return on Assets -68.53% 7% F 3% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 3.12 46% F 39% F
Short Percent 13.66% 16% F 13% F
Beta 0.21 93% A 92% A-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector